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Introduction
Acromegaly defined as by chronic elevations of insulin-
like growth factor-1 (IGF-1) and growth hormone (GH) 
that results in organomegaly.1
Due to a higher risk of systemic complications, 
patients with acromegaly experience increased the rate of 
morbidity and mortality.2,3
Cardiovascular manifestations such as congestive 
heart failure, hypertension, and coronary artery disease 
are common complications in patients with acromegaly 
and cause 60% of the deaths in these patients.4 The 
severity of cardiovascular manifestation related to the 
GH hypersecretion duration and mostly occurs in older 
patients with insufficient controlled acromegaly.5
Recent studies showed the therapeutic efficacy of the 
early intervention, either surgical or medical, on systemic 
complications of acromegaly.6-9
However, acromegaly is a chronic syndrome lasting 
decades, and systemic complications may occur over the 
lifespan of patients. There is limited information regarding 
the effect of surgical resection of pituitary adenoma on 
cardiovascular comorbidities such as cardiomegaly in 
patients with acromegaly. 
The goal of this study was to determinants the incidence 
of cardiomegaly in patients with acromegaly and the 
potential effect of therapeutic intervention in improving 
such complications.
Materials and Methods
A total of 160 patients with acromegaly due to pituitary 
adenoma participated in this study. Acromegaly diagnosed 
was based on clinical manifestations, age-adjusted plasma 
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Abstract
Background: Acromegaly defines as chronic elevations of insulin-like growth factor-1 (IGF-1) and 
growth hormone (GH), which results in enlargement of organs and soft tissues. Cardiovascular 
complications of acromegaly such as cardiomegaly, hypertension contributing to a high risk of 
cardiovascular events. This study aimed to identify the determinants of the prevalence of cardiomegaly 
as cardiovascular comorbidity of acromegaly and the potential effect of the curative intervention.
Methods: A total of 160 patients with acromegaly due to pituitary adenoma participated in this study. 
Acromegaly diagnosed was based on clinical manifestations, age-adjusted plasma IGF-I, and elevated 
plasma GH levels, not suppressible during an oral glucose tolerance test (75 g). Electrocardiogram 
and chest X-ray obtained in all patients. Treatment approaches included transsphenoidal surgery and 
hormonal evaluation performed before and six months after surgery. 
Results: The GH serum level was elevated in all patients before surgery, with a mean of 33.7 ng/
mL that reached 5.7 ng/mL after surgery. Mean IGF-1 was 794.1 ng/mL that reached 395.6 ng/mL 
postoperatively. The prevalence of cardiomegaly was 15% that improved in 5% of patients after trans 
sphenoidal surgery.
Conclusion: Appropriate surgical intervention in acromegaly that complicated by cardiomegaly may 
result in significant improvement of the cardiac structure.
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IGF-I, and insuppressible GH serum levels during an oral 
glucose tolerance test. Chest X-ray and electrocardiogram 
and was obtained from all patients before and six 
months after surgery. The presence of pituitary adenoma 
confirmed by magnetic resonance imaging. In this study, 
cardiomegaly evaluated as a retrospective study of chest 
X-ray (PA) and cardiothoracic ratio (CTR) measurement 
of cardiac and mediastinal size ratios.
The exclusion criteria consisted of previously known 
cases of cardiomyopathy, diabetes mellitus, secondary 
hypertension, and usage of any preoperative medical 
treatment for acromegaly before the study. 
Trans-sphenoidal surgery performed in all cases, and 
hormonal evaluation has done before and 6 months after 
surgical intervention. 
Plasma GH level was measured by immunoradiometric 
assay with a detection limit of 0·2 mU/L, and plasma level 
of IGF-I by an RIA, respectively. IGF-I plasma levels of 
≤ 463 µg/L (20–30 years), ≤ 370 µg/L (31–40 years), ≤ 306 
µg/L (41–50 years) and ≤ 247 µg/L (> 50 years) considered 
as normal.
Patients with GH levels under 2 mU/L after a glucose 
load (75 g) and normal age-corrected IGF-I-values after 
six months considered as well-controlled cases. 
In cases with a GH level > 5 μg/L, treatment continued 
by somatostatin octreotide after surgery. The patients 
were followed up in third and sixth months after surgery 
for evaluating symptoms relief and any case of tumor 
recurrence. 
Results
During the study, 160 patients met the inclusion criteria. 
Their mean age was 39.1, and the standard deviation was 
13.0. The patient’s age ranged from 14 to 72 years old. The 
mean preoperative GH was 33.7 ml/ng, which reached 5.7 
mL/ng after resection (Figure 1). 
The mean pre-operative hormone IGF-1 was 794.1 ml/
ng, which decreased 395.6 ml/ng postoperatively (Figure 
2). In this study, total tumor resection has done in 112 
patients, subtotal resections in 42, and partial resections 
in 6 patients (Table 1). 
Of the 160 patients, 24 had preoperative cardiomegaly 
with a frequency of 15%, of which 30% postoperatively 
had a partial improvement in cardiac symptoms, and 21% 
had no change.
Discussion
Acromegalic cardiomyopathy is a common finding in 
all patients with GH secretive pituitary adenoma. The 
severity of cardiomyopathy is associated with the duration 
of disease and GH serum level before treatment.1,10 
Cardiac complications of excess GH secretion such as 
heart failure and arrhythmias are the leading causes 
of death in patients with pituitary adenoma. Cardiac 
structure change in GH adenomas that occur even in 
the subclinical stages, including cardiac hypertrophy, 
chamber enlargement, ventricular diastolic dysfunction, 
and myocardial dysfunction.10,11 In this study, All of the 
patients had a high level of GH and IGF-1 and, 15 % of 
them had cardiomegaly that measured by chest X-ray. 
Prompt diagnosis and therapeutic intervention are 
essential strategies inpatient with pituitary adenoma high 
level of GH. The first option of treatment in patients 
with acromegaly is endoscopic resection of pituitary 
adenoma.12,13 Removing as much tumor tissue as possible 







Figure 1. Mean Growth Hormone Serum Level Before and After 
Surgery.






Table 1. Size, Characteristics of Invasion, and Degree of Tumor Resection in 
160 Patients With Pituitary Adenomas
Index Number of cases (%)
Tumor Size
Microadenoma (<10 mm) 57 (35.6)
Macroadenoma (>10 mm) 103 (64.4)
Invasion
Invasive neoplasm 62 (38.7)




Total resection 112 (70)
Subtotal resection 42 (26.2)
Partial resection 6 (3.8)
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the primary goal of trans-nasal-sphenoidal endoscopic 
intervention.14 This approach could result in an optimal 
effect of tumor resection with minimum tumor residue.15,16 
Cardiac structural abnormalities and dysfunctional 
are correlate with excessive secretion of GH hormone.17 
Chronic elevation of serum GH and IGF-I due to pituitary 
adenoma could affect myocardium cell receptors, which 
increase myocardial sensitivity to intracellular Ca2+ and 
results to increase myocardial contractility. On the other 
hand, increased protein synthesis and cell volume in 
myocardial cells result in myocardial hypertrophy. Also, 
excess GH secretion results in myocardial degeneration 
and necrosis, interstitial collagen accumulation, and 
fibrosis that lead to cardiac remodeling.18
Currently, GH secretion control by surgical removal of 
the tumor is the treatment of choice in pituitary adenomas 
who complicated with acromegalic cardiomyopathy. 
In the current study, surgical resection of the pituitary 
adenoma and controlling GH secretion and serum levels 
of IGF-1, lead to recovered cardiac structure in some 
patients.
Our results show that myocardial structure 
abnormalities could be partially reversible in patients 
with GH secreting pituitary adenomas, but the best time 
for surgery and to preventing cardiac remodeling needs 
further study. 
Conclusion
Cardiac manifestations in GH secreting pituitary 
adenomas involve needs the standardized approaches 
that include endoscopic surgery with medical therapy 
to maintaining the level of GH is required. Effective 
treatment is essential for pituitary adenomas that 
complicated by acromegaly cardiomyopathy, which may 
improve symptoms and results in a higher quality of life.
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